A clinical trial conducted in the midst of an Ebola epidemic in the Democratic Republic of Congo (DRC) has identified two new drugs that can dramatically cut mortality from the disease, and both are being immediately offered to all patients in an effort to control the country’s worst ever outbreak.
The Pamoja Tulinde Maisha (“together save lives” in Swahili) trial began last November, in four towns stricken by the outbreak. It compared four potential treatments proposed by four different companies: ZMapp, remdesivir, mAb114, and REGN-EB3.
Preliminary data has convinced the trial’s monitoring board to stop the study and randomise all remaining patients to either mAb114 or REGN-EB3.1
Data from the first 499 patients showed that REGN-EB3 had met early stopping criteria, and mAb114 was not far behind. Among all patients who took the drugs, those treated with REGN-EB3 had a mortality rate of 29%, while those who got mAb-114 had a mortality rate of 34%.
Patients treated with ZMapp, the best known Ebola treatment candidate, which was used in the west African epidemic of 2014, had a 49% mortality rate. Those treated with the antiviral remdesivir had a 53% mortality rate.
More than 75% of those who received no treatment have died in the epidemic, which has killed nearly 1900 people out of 2831 confirmed cases.
Researchers believe they can improve outcomes further in patients who are reached early in the course of infection. Among such patients, mortality rates were 6% with REGN-EB3, 11% with mAb114, 24% with ZMapp, and 33% with remdesivir.
Both REGN-EB3 and mAb114, like ZMapp, are monoclonal antibodies, proteins that bind to other proteins on the outer shell of the Ebola virus, which it uses to attach itself to human cells.
Regeneron Pharmaceuticals made REGN-EB3, a cocktail of three such proteins, using antibodies from “humanised” mice infected with Ebola.
The US National Institute of Allergy and Infectious Diseases created mAb114 using antibodies isolated from the blood of a survivor of a 1995 outbreak in DRC. It will be developed by Ridgeback Therapeutics.
“From now on, we will no longer say that Ebola is incurable,” said Jean-Jacques Muyembe-Tamfum, director of the DRC’s Institut National de Recherche Biomédicale, which oversaw the trial. Full results are expected by early October and will appear in a peer reviewed journal soon thereafter.
Muyembe, who was part of the team that discovered the Ebola virus 43 years ago, and who in 1995 became the first doctor to harvest antibodies from survivors, told a press conference that the news of effective treatments would reinvigorate the campaign to end the current outbreak, which has struggled against deep local suspicion in a region plagued by insecurity.
“People think that if you enter a treatment centre, you’ll leave in a coffin,” said Muyembe. But with such high survival rates in the newly infected, he said, “We have a great message: a treatment centre is a place where you can recover and that you leave alive.”
The Latest on: Ebola
via Google News
The Latest on: Ebola
- Covid-19, Ebola, and HIV — Leveraging Lessons to Maximize Impacton October 7, 2020 at 2:45 pm
Download As researchers who have long experience with HIV/AIDS prevention, vaccines, and therapies, some of whom also have experience with Ebola, we believe it is critical to build the response to the ...
- NYC Ebola Doctor Who Trump Blasted 6 Years Ago Fires Back Over Risk of Spreading Viruson October 6, 2020 at 5:13 am
The NYC emergency room physician who survived Ebola in 2014 -- and who then-private citizen Donald Trump blasted for being selfish -- is firing back now that Trump is the president and the one with a ...
- Six years ago, Trump blasted an Ebola-infected doctor. Now he’s hitting back over the president’s coronavirus actions.on October 6, 2020 at 3:49 am
At a time when the president has said that people should not be afraid of an illness that has already killed more than 209,000 Americans, commentators on Monday pointed to his 2014 critique of Spencer ...
- USF researcher using lessons from Ebola in hopes of tracking COVID-19 trajectoryon October 5, 2020 at 8:45 pm
A researcher with the University of South Florida is working to apply methods used to study the Ebola virus outbreaks to look at the spread of the virus causing COVID-19.
- Resurfaced Ebola tweets show that Trump has ignored his own adviceon October 5, 2020 at 2:11 pm
Now Trump’s 2014 tweets about Ebola are casting his pre- and post-diagnosis behavior in what some view as an extremely hypocritical light. In 2014, he repeatedly blamed President Barack Obama for ...
- A Doctor Who’s Fought Ebola And Other Epidemics On Handling The White House Coronavirus Outbreakon October 5, 2020 at 1:16 am
Dr. Mark Kortepeter, who’s fought epidemics on multiple continents, explains what the government needs to do right now to combat the Covid-19 outbreak that’s struck the White House.
- Method used to track Ebola's trajectory being applied to COVID-19on October 5, 2020 at 12:49 am
What exactly happened in Asia that caused SARS-CoV-2 to rapidly spread across the region and then essentially came to a halt there? That's what researchers from the University of South Florida are ...
- WHO 'outraged' by sex abuse reports in Congo Ebola operationon October 2, 2020 at 9:40 am
The World Health Organization (WHO) promised an investigation on Friday into "horrific" allegations of sexual abuse by aid workers combating an Ebola outbreak in Democratic Republic of Congo. "To be ...
- 'God chose me': Congo Ebola survivor finds new purposeon October 1, 2020 at 1:40 pm
For Esperance Nyabintu, catching Ebola was a curse and a gift from God. A year ago the virus killed her husband. Most of her neighbours, friends and family abandoned her, such is the social stigma of ...
- Ex-Obama official on the 'most troubling' difference between Ebola and COVID responseson September 30, 2020 at 7:15 am
The “most troubling” difference between the U.S. response to the Ebola pandemic and its handling of the coronavirus is the nation’s failure to lead a coordinated global effort to tackle the virus, ...
via Bing News